Genovis AB (publ.) GENO
This picture changes. Follow Genovis AB (publ.) free — email when the signal or risk changes + a Sunday weekly brief.
Follow Genovis AB (publ.) freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 2 Aug 2026
General analysis — not personal advice.
NEUTRAL
7/10
Confidence
Hold existing position; consider adding after a strong Q1 report.
The Q2 report confirms 19 % growth and improved cash flow, supporting the existing cautious stance ahead of continued KPL integration.
Market sentiment
8/10
↑
Trend: Improving
Sentiment is neutral to mildly positive following the report that demonstrated underlying growth without FX adjustments.
Price context
The share price at 19.46 SEK sits roughly 33 % below the 52-week high yet 20 % above the low, reflecting a consolidation phase after expansion where the market awaits confirmed growth.
Risk assessment
4/10
Dilution:
Low
Profitable with strong cash reduces funding need
Jurisdiction:
Low
Sweden and Western markets, low political risk
Execution:
Medium
Integration and commercialization may take longer
Recent changes
- Report shows continued organic growth and strong cash flow following the KPL acquisition.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
Genovis AB (publ.) develops and sells enzyme-based tools ("SmartEnzymes") used in development and quality control of biologic drugs. The company is profitable with high gross margins and expanded its portfolio via Sequrna (RNase inhibitors) targeting RNA/NGS workflows. Growth is supported by demand in antibodies/ADCs and related analytical and conjugation processes.
Sector:
Life science tools and enzyme technology
Type:
Biotech
Next report
10 Nov 2026
Q3
Catalysts
Unknown
ADC license milestones
High
Unknown
Integration of KPL proteases
High
Horizon:
Bull case
Strong underlying product sales and improved cash flow support profitability and growth.
Bear case
High valuation leaves limited room for disappointment if organic growth slows after the acquisition.
Signal rationale (informational)
The Q2 report confirms 19 % growth and improved cash flow, supporting the existing cautious stance ahead of continued KPL integration.
Recent news
- Redeye published an updated analysis on 28 July highlighting positive H2 2026 development despite temporarily higher costs. The share trades at 19.58 SEK after a 2.3 % weekly decline.
Key figures
Revenue
H1 2026
SEK 67.8M
Revenue TTM
FY 2025
SEK 129M
EBITDA
H1 2026
SEK 19.8M
Net income
H1 2026
SEK 0.1
Cash
H1 2026
SEK 24.4M
Price & valuation
Last close
SEK 19.82
1 week
+2.5 %
3 months
-5.6 %
12 months
-26.9 %
From 52w high
-26.9 %
From 52w low
+22.6 %
Exchange
First North
Type
Biotech
Sector
Life science tools and enzyme technology
This picture changes. Follow Genovis AB (publ.) free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.